galliapharm 0.74-1.85 gbq radionuklidigeneraattori
eckert & ziegler radiopharma gmbh - gallium (68ga) chloride, germanium (68ge) chloride - radionuklidigeneraattori - 0.74-1.85 gbq - muut diagnostiset radioaktiiviset lÄÄkevalmisteet
tanonalla 5 mg / 2.5 mg depottabletti
sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 5 mg / 2.5 mg - oksikodoni ja naloksoni
tanonalla 10 mg / 5 mg depottabletti
sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 10 mg / 5 mg - oksikodoni ja naloksoni
tanonalla 20 mg / 10 mg depottabletti
sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 20 mg / 10 mg - oksikodoni ja naloksoni
tanonalla 30 mg / 15 mg depottabletti
sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 30 mg / 15 mg - oksikodoni ja naloksoni
tanonalla 40 mg / 20 mg depottabletti
sandoz a/s - oxycodone hydrochloride, naloxone hydrochloride dihydrate - depottabletti - 40 mg / 20 mg - oksikodoni ja naloksoni
alpha ject 3000 injektioneste, emulsio
pharmaq as - aeromonas salmonicida var salmonicida -bacteria, inactivated, listonella anquillarum, serotype 02a, inactivated, listonella anguillarum, serotype 01, inactivated - injektioneste, emulsio
somakit toc
advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. kun radioaktiiviseen merkitsemiseen, jossa gallium - (68ga) kloridi ratkaisu, ratkaisu gallium (68ga) edotreotide saatu on tarkoitettu positroniemissiotomografia (pet) kuvantaminen somatostatiini-reseptorien yliekspressio aikuisille potilaille, joilla on todettu tai epäillään hyvin eriytetty maha-enteropancreatic neuroendokriinisiä kasvaimet (gep-net) paikallistamisen ensisijainen kasvaimia ja niiden etäpesäkkeitä.
gallium citrate ga-67 37 mbq/ml injektioneste, liuos
ge healthcare limited - gallii (67ga) citras - injektioneste, liuos - 37 mbq/ml - gallium(67ga)sitraatti
blincyto
amgen europe b.v. - blinatumomab - prekursorisolujen lymfoblastinen leukemia-lymfooma - antineoplastiset aineet - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.